Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Obecabtagene Autoleucel for B-Cell Acute Lymphoblastic Leukemia.
Journal: JAMA
Published: February 10, 2025
Regulatory Aspects of Gene Therapy: The Regulatory Life Cycle.
Journal: Hematology/oncology clinics of North America
Published: June 30, 2022
FDA Approval Summary: Brexucabtagene Autoleucel for Treatment of Adults With Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia.
Journal: The oncologist
Published: April 26, 2022
FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Follicular Lymphoma.
Journal: The oncologist
Published: November 05, 2021
Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Journal: European journal of cancer (Oxford, England : 1990)
Published: September 28, 2021
Patient-Reported Outcomes in Pediatric Cancer Registration Trials: A US Food and Drug Administration Perspective.
Journal: Journal of the National Cancer Institute
Published: January 28, 2021
FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 31, 2018
A pan-inhibitor of DASH family enzymes induces immune-mediated regression of murine sarcoma and is a potent adjuvant to dendritic cell vaccination and adoptive T-cell therapy.
Journal: Journal of immunotherapy (Hagerstown, Md. : 1997)
Published: September 03, 2013
Showing 1-8 of 8
Last Updated: 09/26/2026